These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34789985)

  • 1. Effect of spiramycin versus aminoguanidine and their combined use in experimental toxoplasmosis.
    Omar M; Abaza BE; Mousa E; Ibrahim SM; Rashed HE; Farag TI
    J Parasit Dis; 2021 Dec; 45(4):1014-1025. PubMed ID: 34789985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel insights on the therapeutic effect of levamisole on the chronic toxoplasmosis in mice model.
    Zoghroban HS; Elmansory BM; Issa YA; Eltokhy AK; Abo Safia HS; El Maghraby GM; Salama AM
    Exp Parasitol; 2023 May; 248():108515. PubMed ID: 36958594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of silver nanoparticles and human platelet rich-plasma versus traditional therapy in the treatment of murine chronic toxoplasmosis.
    Ibrahim SM; Al-Ghandour AMF; Mohamed SMA; Foaad HHM; El-Bahaie ES
    J Parasit Dis; 2024 Jun; 48(2):217-228. PubMed ID: 38840885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA mmu-miR-511-5p: A promising Diagnostic Biomarker in Experimental Toxoplasmosis Using Different Strains and Infective Doses in Mice with Different Immune States Before and After Treatment.
    Mady RF; El-Temsahy MM; Issa YA; Zaghloul AS; Khedr SI
    Acta Parasitol; 2024 Jun; 69(2):1253-1266. PubMed ID: 38743178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Nigella sativa oil- and wheat germ oil-loaded metal organic frameworks on chronic murine toxoplasmosis.
    Mohammad OS; El Naggar HM; Abdelmaksoud HF; Barakat AM; Abdelhameed RM; Shehata MAS
    Acta Trop; 2023 Mar; 239():106823. PubMed ID: 36608751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of honeybee venom loaded nanoparticles for the treatment of chronic toxoplasmosis: parasitological, histopathological, and immunohistochemical studies.
    El Naggar HM; Anwar MM; Khayyal AE; Abdelhameed RM; Barakat AM; Sadek SAS; Elashkar AM
    J Parasit Dis; 2023 Sep; 47(3):591-607. PubMed ID: 37520202
    [No Abstract]   [Full Text] [Related]  

  • 7. Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model.
    Abdel-Wahab AA; Shafey DA; Selim SM; Sharaf SA; Mohsen KK; Allam DM; Elkhadry SW; Gouda MA
    Parasitol Res; 2024 Jul; 123(7):286. PubMed ID: 39046555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice.
    Etewa SE; El-Maaty DAA; Hamza RS; Metwaly AS; Sarhan MH; Abdel-Rahman SA; Fathy GM; El-Shafey MA
    J Parasit Dis; 2018 Mar; 42(1):102-113. PubMed ID: 29491568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.
    Chew WK; Segarra I; Ambu S; Mak JW
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1762-8. PubMed ID: 22271863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remarkable histopathological improvement of experimental toxoplasmosis after receiving spiramycin-chitosan nanoparticles formulation.
    Allam AF; Hagras NA; Farag HF; Osman MM; Shalaby TI; Kazem AH; Shehab AY; Mogahed NMFH
    J Parasit Dis; 2022 Mar; 46(1):166-177. PubMed ID: 35299902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin reduced brain parasite burden in a chronic toxoplasmosis
    Nishi L; Santana PL; Evangelista FF; Beletini LF; Souza AH; Mantelo FM; Souza-Kaneshima AM; Costa IN; Falavigna-Guilherme AL
    Parasitology; 2020 Mar; 147(3):303-309. PubMed ID: 31727196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Anti-Toxoplasmosis Efficiency of
    Wakid MH; Alsulami MN; Farid M; El Kholy WA
    Infect Drug Resist; 2023; 16():7743-7758. PubMed ID: 38144223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ginger Is a Potential Therapeutic for Chronic Toxoplasmosis.
    El-Kady AM; Al-Megrin WAI; Abdel-Rahman IAM; Sayed E; Alshehri EA; Wakid MH; Baakdah FM; Mohamed K; Elshazly H; Alobaid HM; Qahl SH; Elshabrawy HA; Younis SS
    Pathogens; 2022 Jul; 11(7):. PubMed ID: 35890042
    [No Abstract]   [Full Text] [Related]  

  • 14. [Investigation of combined effectiveness of spiramycin and beta-glucan in mice models of acute toxoplasmosis and determination of IL-10, IL-12 and TNF-α levels].
    Büyükbaba Boral O; Sönmez Tamer G; Keçeli Özcan S; Sönmez N; Işsever H; Tekeli F
    Mikrobiyol Bul; 2012 Jul; 46(3):446-55. PubMed ID: 22951656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multimodality therapeutic application on Toxoplasma gondii encephalitis utilizing Spiramycin and 'de novo' Ferula asafetida in immunodeficient mice.
    Almurshidi BH; Fahmy Z; El-Shennawy A; Selim EAH; Hammam OA; Okasha H; Al-Hajj W; Mahmoud SA; Abuelenain GL
    Parasite Immunol; 2023 Dec; 45(12):e13014. PubMed ID: 37807942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex dichotomy in the course of experimental latent toxoplasmosis.
    Hegazy MM; Elmehankar MS; Azab MS; El-Tantawy NL; Abdel-Aziz A
    Exp Parasitol; 2019 Jul; 202():15-21. PubMed ID: 31078550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of acute experimental toxoplasmosis by spiramycin-loaded chitosan nanoparticles.
    Hagras NA; Allam AF; Farag HF; Osman MM; Shalaby TI; Fawzy Hussein Mogahed NM; Tolba MM; Shehab AY
    Exp Parasitol; 2019 Sep; 204():107717. PubMed ID: 31228418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of
    El Saftawy EA; Turkistani SA; Alghabban HM; Albadawi EA; Ibrahim BE; Morsy S; Farag MF; Al Hariry NS; Shash RY; Elkazaz A; Amin NM
    Food Waterborne Parasitol; 2023 Sep; 32():e00201. PubMed ID: 37719029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of isoflavone biochanin A in chronic experimental toxoplasmosis: impact on inflammation.
    Aboukamar WA; Elhenawy AA; Elmehankar MS; Elzoheiry MA; El-Gamal R; Elabbasy LM; Hany H; Nabih N
    Parasitol Res; 2022 Aug; 121(8):2405-2414. PubMed ID: 35710847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Nigella sativa oil on experimental toxoplasmosis.
    Mady RF; El-Hadidy W; Elachy S
    Parasitol Res; 2016 Jan; 115(1):379-90. PubMed ID: 26446086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.